Research Article
Accurate Diagnostics of Lung Cancer Using Prime Model Generative AI
Philip de Melo*
Issue:
Volume 13, Issue 3, September 2025
Pages:
81-97
Received:
27 April 2025
Accepted:
19 May 2025
Published:
4 July 2025
DOI:
10.11648/j.crj.20251303.11
Downloads:
Views:
Abstract: Health informatics plays a crucial role in the early detection of lung cancer by enhancing the collection, analysis, and application of patient data in clinical settings. It enables the integration of data from electronic health records (EHRs), imaging, pathology reports, and even genomic information. Artificial Intelligence (AI) and Machine Learning (ML) technologies further support lung cancer detection by tracking disease progression over time, identifying changes that may suggest malignancy, and reducing false-positive and unnecessary procedures. A fundamental challenge, however, remains: many existing lung cancer prediction models report accuracy below 80%, emphasizing the need for more effective classification techniques. In this work, we introduce a novel approach that significantly improves predictive accuracy, achieving rates between 95% and 98% a notable advancement over current methods using the same dataset. This improvement is driven by a recently developed Generative AI technology, considered one of the most powerful tools for enhancing the performance of health informatics systems.
Abstract: Health informatics plays a crucial role in the early detection of lung cancer by enhancing the collection, analysis, and application of patient data in clinical settings. It enables the integration of data from electronic health records (EHRs), imaging, pathology reports, and even genomic information. Artificial Intelligence (AI) and Machine Learni...
Show More
Research Article
Dual Targeting of Brain Tumors and Their Environment by Bumetanide and Mebendazole
William Bourgeois,
Natalia Lozovaya,
Marianna Silvano,
Anice Moumen,
Eric Delpire,
Emmanuel Gay,
Florian Le Lann,
Arnaud Lazard,
Dominique Hoffman,
Nikolay Zhukovsky,
François Berger,
Yehezkel Ben-Ari*
Issue:
Volume 13, Issue 3, September 2025
Pages:
98-122
Received:
29 May 2025
Accepted:
16 June 2025
Published:
7 July 2025
DOI:
10.11648/j.crj.20251303.12
Downloads:
Views:
Abstract: Background: The anti-epileptic NKCC1 inhibitor Bumetanide (BUM) and the microtubule acting anthelminthic agent Mebendazole (MEB), have anti-cancer properties. Tumor & its environment generate neuronal hyperactivity that aggravates the clinical outcome suggesting that their combination might block hyperactivity (BUM) and augment cell death (MEB). Methods: We tested the effects of the combo on i) NKCC1 activity in human cell lines, ii) electrical activity recorded from mouse hippocampal neurons & tumors freshly resected from patients, iii) glioblastoma-brain co-cultures, iv) cell death in human tumoroids. Results: BUM efficiently inhibited NKCC1 & unexpectedly, MEB applications also via a likely indirect action. In rodent hippocampal neurons, BUM blocked GABAergic Giant Depolarizing Potentials and seizures and co-applications of MEB produced a fourfold increase of BUM's efficacy. In freshly removed brain tumors, E GABA reversal recorded with single GABA channels was highly depolarized (close to -25 mV) in keeping with NKCC1 over activity. BUM fully blocked ongoing epileptic activity. In GBM-Brain cultures, the combo produced stronger effects then independent applications of MEB or BUM. In tumoroids, the combo also efficiently produced strong cell death & morphological changes in some tumors. Conclusion: The combination of BUM & MEB acts complementarily on brain tumors, the former blocking seizures, and the latter producing cell death. Their combination increases their hyperactivity inhibitory actions and cell death. The combo might therefore be used to treat brain tumors combining 2 different mechanisms and targets.
Abstract: Background: The anti-epileptic NKCC1 inhibitor Bumetanide (BUM) and the microtubule acting anthelminthic agent Mebendazole (MEB), have anti-cancer properties. Tumor & its environment generate neuronal hyperactivity that aggravates the clinical outcome suggesting that their combination might block hyperactivity (BUM) and augment cell death (MEB). Me...
Show More
